6-ISOPROPYL-2-METHOXY-4H-BENZO[1,3,2]DIOXAPHOSPHININE 2-SULFIDE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	YXOCRZRMAHAZPK-UHFFFAOYSA-N
Smiles	COP1(=S)OCc2cc(ccc2O1)C(C)C
InChI	InChI=1S/C11H15O3PS/c1-8(2)9-4-5-11-10(6-9)7-13-15(16,12-3)14-11/h4-6,8H,7H2,1-3H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C11H15O3PS
Molecular Weight	258.27
AlogP	3.26
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	2.0
Polar Surface Area	69.59
Molecular species	None
Aromatic Rings	1.0
Heavy Atoms	16.0

Assay Description	Organism	Bioactivity
Growth inhibition of Athelia rolfsii at 1000 ppm by agar dilution method	Athelia rolfsii	100.0 %
Growth inhibition of Athelia rolfsii at 100 ppm by agar dilution method	Athelia rolfsii	96.9 %
Growth inhibition of Athelia rolfsii at 50 ppm by agar dilution method	Athelia rolfsii	92.5 %
Growth inhibition of Pythium sp. at 1000 ppm by agar dilution method	Pythium	82.6 %
Growth inhibition of Athelia rolfsii at 10 ppm by agar dilution method	Athelia rolfsii	62.0 %
Growth inhibition of Pythium sp. at 100 ppm by agar dilution method	Pythium	71.1 %
Growth inhibition of Pythium sp. at 10 ppm by agar dilution method	Pythium	0.0 %
Growth inhibition of Pythium sp. at 50 ppm by agar dilution method	Pythium	50.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2272848
PubChem	76323477

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).